| 參考文獻 | 1. Wilkins MR, Sanchez JC, Williams KL, Hochstrasser DF. Current challenges and future applications for protein maps and post-translational vector maps in proteome projects. Electrophoresis 1996; 17(5):830-8.
2. Wilkins MR, Hochstrasser DF, Sanchez JC, Bairoch A, Appel RD. Integrating two-dimensional gel databases using the Melanie II software. Trends Biochem Sci 1996 21(12):496-7.
3. Viswanatha DS, Chen I, Liu PP, Slovak ML, Rankin C, Head DR. Characterization and use of an antibody detecting the CBFbeta-SMMHC fusion protein in inv (16) /t (16;16) -associated acute myeloid leukemias. Blood 1998; 91:1882–90.
4. Kuban DA, El-Mahdi A, Schellhammer PE. PSA for outcome prediction and posttreatment evaluation following radiation for prostate canceer: do we know how to use it? Semin Oncol 1998; 8:72-80.
5. Lindblom A, Liljegren A. Tumor markers in malignancies. Br Med J 2000; 320:424–7.
6. Johnson PJ. Role of alpha-fetoprotein in the diagnosis and management of hepatocellular carcinoma. J Gastroenterol Hepatol 1999; 14:S32–6. Suppl.
7. Putnam FW. The plasma proteins structure, function, and genetic control. Academic Press, New York 1975-1987.
8. Poon TCW, Johnson PJ. Proteome analysis and its impact on the discovery of serological tumor marker. Clinica Chimica Acta 2001; 313:231-239.
9. Anderson NL and Anderson NG. High resolution two-dimensional electrophoresis of human plasma proteins. Proc Natl Acad Sci U.S.A. 1977; 74:5421–5425.
10. Anderson NL and Anderson, NG. A two-dimensional gel database of human plasma proteins. Electrophoresis 1991; 12:883–906.
11. Anderson, NG, Willis DD, Holladay DW, Caton JE, Holleman JW, Eveleigh J, Attrill JE, Ball FL, and Anderson NL. Analytical techniques for cell fractions XIX. The cyclum: an automatic system for cyclic chromatography. Anal Biochem 1975; 66:159–174.
12. Ping P, Vondriska TM, Creighton CJ, Gandhi TK, Yang Z, Menon R, Kwon MS, Cho SY, Drwal G, Kellmann M, Peri S, Suresh S, Gronborg M, Molina H, Chaerkady R, Rekha B, Shet AS, Gerszten RE, Wu H, Raftery M, Wasinger V, Schulz-Knappe P, Hanash SM, Paik YK, Hancock WS, States DJ, Omenn GS, Pandey A. A functional annotation of subproteomes in human plasma. Proteomics 2005 Aug; 5(13):3506-19.
13. Simpson RJ. Introduction to proteomics, Proteins and Proteomics, a laboratory manual. Cold Spring Harbor Laboratory Press, 2002.
14. Anderson NL, Anderson NG. The human plasma proteome. Mol Cel Proteomics 2002; 1(11):845-867.
15. Chan AT, Ho S, Yim AP, Chang AR, Cheng P, Yuen J. Primary mediastinal malignant germ cell tumor. Single institution experience in Chinese patients and correlation with specific alpha-fetoprotein bends. Acta Oncol 1996; 35:221–7.
16. Specialty Laboratories Directory of services, and use and interpretation of tests. Santa Monica, CA. 2001.
17. Carpelan-Holmstrom M, Louhimo J, Stenman UH, Alfthan H et al. CEA, CA 19-9 and CA 72-4 improve the diagnostic accuracy in gastrointestinal cancers. Anticancer Res 2002, 22, 2311–2316.
18. Louhimo J, Finne P, Alfthan H, Stenman UH et al. Combination of HCGbeta, CA 19-9 and CEA with logistic regression improves accuracy in gastrointestinal malignancies. Anticancer Res 2002, 22, 1759–1764.
19. Hayakawa T, Naruse S, Kitagawa M, Ishiguro H et al. A prospective multicenter trial evaluating diagnostic validity of multivariate analysis and individual serum marker in differential diagnosis of pancreatic cancer from benign pancreatic diseases. Int J Pancreatol 1999, 25, 23–29.
20. Clarke CH, Buckley JA, Fung ET. SELDI-TOF-MS proteomics of breast cancer. Clin Chem Lab Med 2005; 43(12):1314-1320.
21. Hu Y, Zhang S, Yu J, Liu J, Zheng S. SELDI-TOF-MS: the proteomics and bioinformatics approaches in the diagnosis of breast cancer. Breast 2005; 14(4):250-255.
22. Li J, Zhao J, Yu X, Lange J, Kuerer H, Krishnamurthy S, Schilling E, Khan SA, Sukumar S, Chan DW. Identification of biomarkers for breast cancer in nipple aspiration and ductal lavage fluid. Clin Cancer Res 2005; 11(23):8312-8320.
23. Mathelin C, Cromer A, Wendling C, Tomasetto C, Rio MC. Serum biomarkers for detection of breast cancers: a prospective study. Breast Cancer Res Treat 2005;1-8.
24. Pawlik TM, Fritsche H, Coombes KR, Xiao L, Krishnamurthy S, Hunt KK, Pusztai L, Chen JN, Clarke CH, Arun B, Hung MC, Kuerer HM. Significant differences in nipple aspirate fluid protein expression between healthy women and those with breast cancer demonstrated by time-of-flight mass spectrometry. Breast Cancer Res Treat 2005; 89(2):149-157.
25. Laronga C, Becker S, Watson P, Gregory B, Cazares L, Lynch H, Perry RR, Wright GL Jr., Drake RR, Semmes OJ. SELDI-TOF serum profiling for prognostic and diagnostic classification of breast cancers. Dis Markers 2003; 19(4-5):229-238.
26. Le L, Chi K, Tyldesley S, Flibotte S, Diamond DL, Kuzyk MA, Sadar MD. Identification of serum amyloid A as a biomarker to distinguish prostate cancer patients with bone lesions. Clin Chem 2005; 51(4):695-707.
27. Semmes OJ, Feng Z, Adam BL, Banez LL, Bigbee WL, Campos D, Cazares LH, Chan DW, Grizzle WE, Izbicka E, Kagan J, Malik G, McLerran D, Moul JW, Partin A, Prasanna P, Rosenzweig J, Sokoll LJ, Srivastava S, Srivastava S, Thompson I, Welsh MJ, White N, Winget M, Yasui Y, Zhang Z, Zhu L. Evaluation of serum protein profiling by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry for the detection of prostate cancer: I. Assessment of platform reproducibility. Clin Chem 2005; 51(1):102-112.
28. Grizzle WE, Semmes OJ, Basler J, Izbicka E, Feng Z, Kagan J, Adam BL, Troyer D, Srivastava S, Thornquist M, Zhang Z, Thompson IM. The early detection research network surface-enhanced laser desorption and ionization prostate cancer detection study: A study in biomarker validation in genitourinary oncology. Urol Oncol 2004; 22(4):337-343.
29. Grizzle WE, Adam BL, Bigbee WL, Conrads TP, Carroll C, Feng Z, Izbicka E, Jendoubi M, Johnsey D, Kagan J, Leach RJ, McCarthy DB, Semmes OJ, Srivastava S, Srivastava S, Thompson IM, Thornquist MD, Verma M, Zhang Z, Zou Z. Serum protein expression profiling for cancer detection: validation of a SELDI-based approach for prostate cancer. Dis Markers 2003; 19(4-5):185-195.
30. Jr GW, Cazares LH, Leung SM, Nasim S, Adam BL, Yip TT, Schellhammer PF, Gong L, Vlahou A. Proteinchip(R) surface enhanced laser desorption/ionization (SELDI) mass spectrometry: a novel protein biochip technology for detection of prostate cancer biomarkers in complex protein mixtures. Prostate Cancer Prostatic Dis 1999; 2(5/6):264-276.
31. Britten RA, Hardy C, Vlahou A, Gregory B, Giri PS, Drake R. Identification of reproducible low mass SELDI protein profiles specific to cisplatin resistance in human ovarian cancer cells. Oncol Rep 2005; 14(5):1323-1330.
32. Kong F, Nicole WC, Xiao X, Feng Y, Xu C, He D, Zhang Z, Yu Y. Using proteomic approaches to identify new biomarkers for detection and monitoring of ovarian cancer. Gynecol Oncol 2005.
33. Kozak KR, Su F, Whitelegge JP, Faull K, Reddy S, Farias-Eisner R. Characterization of serum biomarkers for detection of early stage ovarian cancer. Proteomics 2005; 5(17):4589-4596.
34. Moshkovskii SA, Serebryakova MV, Kuteykin-Teplyakov KB, Tikhonova OV, Goufman EI, Zgoda VG, Taranets IN, Makarov OV, Archakov AI. Ovarian cancer marker of 11.7 kDa detected by proteomics is a serum amyloid A1. Proteomics 2005; 5(14):3790-3797.
35. Vlasova MA, Moshkovskii SA, Safarova MP, Makarov OV, Archakov AI. [Molecular diagnostics of ovarian cancer using proteome techniques]. Biomed Khim 2005; 51(4):367-383.
36. Yu JS, Ongarello S, Fiedler R, Chen XW, Toffolo G, Cobelli C, Trajanoski Z. Ovarian cancer identification based on dimensionality reduction for high-throughput mass spectrometry data. Bioinformatics 2005; 21(10):2200-2209.
37. Vlahou A, Schorge JO, Gregory BW, Coleman RL. Diagnosis of Ovarian Cancer Using Decision Tree Classification of Mass Spectral Data. J Biomed Biotechnol 2003; 2003(5):308-314.
38. Ardekani AM, Liotta LA, Petricoin EF III. Clinical potential of proteomics in the diagnosis of ovarian cancer. Expert Rev Mol Diagn 2002; 2(4):312-320.
39. Ruetschi U, Zetterberg H, Podust VN, Gottfries J, Li S, Hviid SA, McGuire J, Karlsson M, Rymo L, Davies H, Minthon L, Blennow K. Identification of CSF biomarkers for frontotemporal dementia using SELDI-TOF. Exp Neurol 2005; 196(2):273-281.
40. Wiltfang J, Lewczuk P, Riederer P, Grunblatt E, Hock C, Scheltens P, Hampel H, Vanderstichele H, Iqbal K, Galasko D, Lannfelt L, Otto M, Esselmann H, Henkel AW, Kornhuber J, Blennow K. Consensus paper of the WFSBP Task Force on Biological Markers of Dementia: the role of CSF and blood analysis in the early and differential diagnosis of dementia. World J Biol Psychiatry 2005; 6(2):69-84.
41. Sun B, Rempel HC, Pulliam L. Loss of macrophage-secreted lysozyme in HIV-1-associated dementia detected by SELDI-TOF mass spectrometry. AIDS 2004; 18(7):1009-1012.
42. Ranganathan S, Williams E, Ganchev P, Gopalakrishnan V, Lacomis D, Urbinelli L, Newhall K, Cudkowicz ME, Brown RH Jr., Bowser R. Proteomic profiling of cerebrospinal fluid identifies biomarkers for amyotrophic lateral sclerosis. J Neurochem 2005; 95(5):1461-1471.
43. Davidsson P, Sjogren M. Proteome studies of CSF in AD patients. Mech Ageing Dev 2005.
44. Rai AJ, Stemmer PM, Zhang Z, Adam BL, Morgan WT, Caffrey RE, Podust VN, Patel M, Lim LY, Shipulina NV, Chan DW, Semmes OJ, Leung HC. Analysis of Human Proteome Organization Plasma Proteome Project (HUPO PPP) reference specimens using surface enhanced laser desorption/ionization-time of flight (SELDI-TOF) mass spectrometry: multi-institution correlation of spectra and identification of biomarkers. Proteomics 2005; 5(13):3467-3474.
45. Omenn GS, States DJ, Adamski M et al. Overview of the HUPO Plasma Proteome Project: results from the pilot phase with 35 collaborating laboratories and multiple analytical groups, generating a core dataset of 3020 proteins and a publicly-available database. Proteomics 2005; 5(13):3226-3245.
46. Haab BB. Antibody arrays in cancer research. Mol Cell Proteomics 2005; 4(4):377-383.
47. Haab BB, Geierstanger BH, Michailidis G et al. Immunoassay and antibody microarray analysis of the HUPO Plasma Proteome Project reference specimens: systematic variation between sample types and calibration of mass spectrometry data. Proteomics 2005; 5(13):3278-3291.
48. Haab BB. Multiplexed protein analysis using antibody microarrays and label-based detection. Methods Mol Med 2005; 114:183-194.
49. Miller JC, Zhou H, Kwekel J et al. Antibody microarray profiling of human prostate cancer sera: antibody screening and identification of potential biomarkers. Proteomics 2003 Jan; 3(1):56-63.
50. Haab BB, Zhou H. Multiplexed protein analysis using spotted antibody microarrays. Methods Mol Biol 2004; 264:33-45.
51. Haab BB. Methods and applications of antibody microarrays in cancer research. Proteomics 2003; 3(11):2116-2122.
52. Haab BB, Dunham MJ, Brown PO. Protein microarrays for highly parallel detection and quantitation of specific proteins and antibodies in complex solutions. Genome Biol 2001; 2(2):RESEARCH0004.
53. Haab BB. Advances in protein microarray technology for protein expression and interaction profiling. Curr Opin Drug Discov Devel 2001; 4(1):116-123.
54. He F. Human liver proteome project: plan, progress, and perspectives. Mol Cell Proteomics. 2005 Dec;4(12):1841-8.
55. Gao J, Gao Y, Yand J et al. Proteomics-based generation and characterization of monoclonal antibodies against human liver mitochondrial proteins. Proteomics. 2006 Jan;6(2):427-37.
|
|---|
